RESTON, Va.--(BUSINESS WIRE)--Aptiv Solutions, a biopharmaceutical and medical device development services company, and leader in adaptive clinical trial design, simulation, and execution, announced today the appointment of key internal executives to global management roles.
Dr. Phil Birch has been named to the newly created position of Senior Vice President and Corporate Brand Manager for Adaptive Clinical Trials. In this global position, Dr. Birch will liaise closely with the Aptiv Solutions Innovation Center, Business Development, and Operational teams to ensure strategic growth within the adaptive clinical trials sector. Duties of the Corporate Brand Manager will include brand development, market education, developing strategic partnerships and heightening of customer focus across Aptiv Solutions business units. Dr Birch, who was previously Senior Vice President of Global Regulatory, has a wealth of experience in R&D, Strategic Marketing and Corporate Development having held senior management positions for these roles in the Pharma, Biotech and Service industries.
Carolyn Belcher has been announced as the successor to Dr. Birch and will take up the position of Senior Director and Global Head of the Aptiv Solutions Regulatory Business Unit. In her new role, Ms. Belcher will oversee the worldwide regulatory team, which provides first class regulatory support for clinical development programs and market approval. Ms. Belcher will ensure that Aptiv Solutions remains the industry leader for assisting clients with their regulatory strategy including the implementation of adaptive clinical trials.
Ms. Belcher recently joined Aptiv Solutions through the acquisition of SRA Global Clinical Development (GCD) where she was Senior Director and Global Head of Regulatory Affairs and Strategic Drug Development Services. Ms Belcher has over 17 years experience within the Pharmaceutical and Health Care Industry and during her tenure at SRA GCD, she led the regulatory affairs team which managed projects and assignments from early phase development through to post marketing activities. Prior to joining SRA, Ms. Belcher was employed by Novartis and before that the UK National Health Service as a Clinical Research Scientist working within the field of cardiothoracic transplantation.
“Our organization is committed to developing customized adaptive clinical trial services for our clients,” said Pat Donnelly, Chairman and CEO of Aptiv Solutions. “This past year, we have seen a dramatic increase in sponsor interest in pursuing adaptive design clinical trials and as an organisation we are aligning strong leadership and expertise to focus internal resources to help our clients develop, design and execute best-in-class adaptive clinical programs.”
About Aptiv Solutions
Aptiv Solutions is a global biopharmaceutical and medical device development services company focused on recognizing, understanding and enabling clients to capitalize on rapid and fundamental changes facing companies developing products in the pharmaceutical, biotech and medical device market. The company offers clients an extensive portfolio of innovative services including adaptive clinical trials, translational research services, regulatory services, pharmacovigilance, clinical staffing and the operational support of a global clinical research organization. Aptiv Solutions has over 850 professionals in North America, Europe, the Middle East, Japan, and Australia. Visit the website at www.aptivsolutions.com.